These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18270046)

  • 21. Circadian optimization of treatment time using DNA replication-dependent cell-cycle-specific halogenated pyrimidines.
    Klevecz RR; Brown LP; Morgan RJ; Carroll M
    J Infus Chemother; 1995; 5(1):15-9. PubMed ID: 7634171
    [No Abstract]   [Full Text] [Related]  

  • 22. Modelling and simulation of chemotherapy of haematological and gynaecological cancers.
    Nani FK; Oğuztöreli MN
    IMA J Math Appl Med Biol; 1999 Mar; 16(1):39-91. PubMed ID: 10335600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor cell kinetics and cancer chemotherapy.
    Toal DR
    Crit Care Update; 1981 Sep; 8(9):34-7. PubMed ID: 6912803
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active targeting schemes for nanoparticle systems in cancer therapeutics.
    Byrne JD; Betancourt T; Brannon-Peppas L
    Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational modeling of synchronization process of the circadian timing system of mammals.
    Cardoso FR; de Oliveira Cruz FA; Silva D; Cortez CM
    Biol Cybern; 2009 May; 100(5):385-93. PubMed ID: 19367410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules.
    Bernard S; Cajavec Bernard B; Lévi F; Herzel H
    PLoS Comput Biol; 2010 Mar; 6(3):e1000712. PubMed ID: 20333244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs.
    Al-Obaid AM; Abdel-Hamide SG; El-Kashef HA; Abdel-Aziz AA; El-Azab AS; Al-Khamees HA; El-Subbagh HI
    Eur J Med Chem; 2009 Jun; 44(6):2379-91. PubMed ID: 18950904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of circadian regulation in cancer.
    Gery S; Koeffler HP
    Cold Spring Harb Symp Quant Biol; 2007; 72():459-64. PubMed ID: 18419305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An integrated network-based mechanistic model for tumor growth dynamics under drug administration.
    Ribeiro D; Pinto JM
    Comput Biol Med; 2009 Apr; 39(4):368-84. PubMed ID: 19285661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor cells proliferation and migration under the influence of their microenvironment.
    Friedman A; Kim Y
    Math Biosci Eng; 2011 Apr; 8(2):371-83. PubMed ID: 21631135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin.
    Oda A; Katayose Y; Yabuuchi S; Yamamoto K; Mizuma M; Shirasou S; Onogawa T; Ohtsuka H; Yoshida H; Hayashi H; Rikiyama T; Kim H; Choe Y; Kim K; Son H; Motoi F; Egawa S; Unno M
    Anticancer Res; 2009 Apr; 29(4):1201-9. PubMed ID: 19414365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The symphony of life. Importance, interaction, and visualization of biological rhythms.
    Moser M; Frühwirth M; Kenner T
    IEEE Eng Med Biol Mag; 2008; 27(1):29-37. PubMed ID: 18270048
    [No Abstract]   [Full Text] [Related]  

  • 34. [Principles of chemotherapy of neoplastic diseases in children].
    Matysiak M; Ochocka M
    Pediatr Pol; 1982 Dec; 57(12):1099-105. PubMed ID: 7182789
    [No Abstract]   [Full Text] [Related]  

  • 35. [Exploiting functional dependencies in cancer cells for the development of targeted therapies].
    Stolze B; Scholl C
    Dtsch Med Wochenschr; 2013 Jun; 138(25-26):1369-72. PubMed ID: 23761060
    [No Abstract]   [Full Text] [Related]  

  • 36. Mathematical modeling of cancer progression and response to chemotherapy.
    Sanga S; Sinek JP; Frieboes HB; Ferrari M; Fruehauf JP; Cristini V
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1361-76. PubMed ID: 17069522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell cycle and effect of antineoplastic drugs: facts and pitfalls.
    Mauro F; Spanò M; Teodori L; Drewinko B; Barlogie B
    Prog Clin Biol Res; 1983; 132C():199-209. PubMed ID: 6634772
    [No Abstract]   [Full Text] [Related]  

  • 38. [Molecular basis of choronopharmacology].
    Koyanagi S
    Seikagaku; 2014 Dec; 86(6):774-7. PubMed ID: 25675816
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer robustness: tumour tactics.
    Kitano H
    Nature; 2003 Nov; 426(6963):125. PubMed ID: 14614483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.